ReviewBiomolecules2022
The Nicotinamide/Streptozotocin Rodent Model of Type 2 Diabetes: Renal Pathophysiology and Redox Imbalance Features.
Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Gadolinium Orthovanadate Nanoparticles Normalizes Glycemia, Insulin Resistance, and Glucose Tolerance in Rats with Experimental Type 2 Diabetes Mellitus.Biological trace element research · 2026Article
- Unraveling Hippocampal and Prefrontal Cortex Alterations in Experimental Type 1 and Type 2 Diabetes: A 100-Day Exploration of Biochemical and Behavioral-Cognitive Dysfunction.Molecular neurobiology · 2026Article
- Characterizing the Antihyperglycemic Activity and Underlying Mechanisms of the Aqueous Extract of the Leaves fromMolecules (Basel, Switzerland) · 2026Article
- Comparative Analysis of Streptozotocin, Streptozotocin-Nicotinamide and Alloxan-Based Diabetes Models in Female Wistar Rats.Methods and protocols · 2026Article
- Understanding the Antihyperglycemic Activity ofMolecules (Basel, Switzerland) · 2026Article
- Propolis alleviates brain tissue damage and oxidative abnormalities in streptozotocin (STZ)-induced diabetes.Journal, genetic engineering & biotechnology · 2026Article
- Renoprotection by 5-Methoxytryptophan in Kidney Disease.Biomolecules · 2026Review
- Article
- Animal models for diabetic kidney disease: perspectives and prospects.Frontiers in veterinary science · 2026Article
- Preclinical Evaluation of Fisetin in the Management of Diabetic Foot Ulcer in Wistar Rats.Current diabetes reviews · 2026Article
- Unravelling the role of natural herbs for the management of diabetes mellitus.Diabetology & metabolic syndrome · 2025Review
- Exploring the hypoglycemic potential of HuGLP-1-loaded bilosomes in controlling type 2 diabetes mellitus.Therapeutic delivery · 2025Article
- Antihyperglycaemic Activity of Standardised Ethanolic Extract ofTropical life sciences research · 2025Article
- Shenzhuo formulation ameliorates diabetic nephropathy by regulating cytochrome P450-mediated arachidonic acid metabolism.World journal of diabetes · 2025Article
- Diosmin Potentiates the Antidiabetic Effects of Linagliptin in Nicotinamide/Streptozotocin-Induced Diabetic Wistar Rats.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effect of feedingVeterinary world · 2025Article
- EFFECT OF DIURNAL INTERMITTENT FASTING (DIF) ON ANTIOXIDANT AND PRO INFLAMMATORY MEDIATORS ACTIVITY IN MALE RAT MODEL OF TYPE 2 DIABETES MELLITUS.African journal of infectious diseases · 2025Article
- Construction and evaluation of a combined model of NAA/STZ-induced type 2 diabetes with carotid balloon injury in SD rats.Frontiers in endocrinology · 2025Article
- Effect ofBiology · 2024Article
- AGEs impair osteogenesis in orthodontic force-induced periodontal ligament stem cells through the KDM6B/Wnt self-reinforcing loop.Stem cell research & therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is a common complication of diabetes mellitus. While there has been a great advance in our understanding of the pathogenesis of DN, no effective managements of this chronic kidney disease are currently available. Therefore, continuing to elucidate the underlying biochemical and molecular mechanisms of DN remains a constant need. In this regard, animal models of diabetes are indispensable tools. This review article highlights a widely used rodent model of non-obese type 2 diabetes induced by nicotinamide (NA) and streptozotocin (STZ). The mechanism underlying diabetes induction by combining the two chemicals involves blunting the toxic effect of STZ by NA so that only a percentage of β cells are destroyed and the remaining viable β cells can still respond to glucose stimulation. This NA-STZ animal model, as a platform for the testing of numerous antidiabetic and renoprotective materials, is also discussed. In comparison with other type 2 diabetic animal models, such as high-fat-diet/STZ models and genetically engineered rodent models, the NA-STZ model is non-obese and is less time-consuming and less expensive to create. Given that this unique model mimics certain pathological features of human DN, this model should continue to find its applications in the field of diabetes research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.